Butterfly Network Reports Preliminary, Unaudited Fourth Quarter 2024 Revenue Growth of Approximately 35% Year over Year
Butterfly Network (NYSE: BFLY) announced preliminary, unaudited Q4 2024 revenue growth of approximately 35% year over year. The digital health company, known for its portable semiconductor-based ultrasound technology, reported exceeding expectations with accelerating growth throughout 2024.
The company plans to release audited fourth quarter and full year 2024 results in late February 2025, along with guidance for 2025. Management expressed confidence in maintaining strong top-line growth with continued fiscal discipline going forward. The company will present a business update at the 43rd J.P. Morgan Healthcare Conference on January 16, 2025.
Butterfly Network (NYSE: BFLY) ha annunciato una crescita preliminare e non verificata del fatturato del quarto trimestre 2024 di circa 35% rispetto all'anno precedente. L'azienda di salute digitale, nota per la sua tecnologia ad ultrasuoni portatile a base di semiconduttori, ha riportato risultati superiori alle aspettative con una crescita accelerata durante tutto il 2024.
L'azienda prevede di pubblicare i risultati auditati del quarto trimestre e dell'anno intero 2024 a fine febbraio 2025, insieme alle previsioni per il 2025. La direzione ha espresso fiducia nel mantenimento di una forte crescita del fatturato con una disciplina fiscale continua in futuro. L'azienda presenterà un aggiornamento commerciale alla 43ª Conferenza Sanitaria J.P. Morgan il 16 gennaio 2025.
Butterfly Network (NYSE: BFLY) anunció un crecimiento preliminar y no auditado de ingresos del cuarto trimestre de 2024 de aproximadamente 35% interanual. La empresa de salud digital, conocida por su tecnología de ultrasonido portátil basada en semiconductores, reportó haber superado las expectativas con un crecimiento acelerado durante todo el 2024.
La empresa planea publicar los resultados auditados del cuarto trimestre y del año completo 2024 a finales de febrero de 2025, junto con proyecciones para 2025. La dirección expresó confianza en mantener un sólido crecimiento de ingresos con una disciplina fiscal continua en adelante. La empresa presentará una actualización comercial en la 43ª Conferencia de Salud J.P. Morgan el 16 de enero de 2025.
버터플라이 네트워크 (NYSE: BFLY)는 2024년 4분기 비감사 수익 성장률이 약 전년 대비 35%에 달했다고 발표했습니다. 반도체 기반의 휴대용 초음파 기술로 알려진 이 디지털 헬스 회사는 2024년 동안 가속화된 성과로 기대를 초과 달성했습니다.
회사는 2024년 4분기 및 연간 감사 결과를 2025년 2월 말에 발표할 예정이며, 2025년도에 대한 가이던스도 제공할 것입니다. 경영진은 앞으로도 지속적인 재정 관리로 강력한 매출 성장 유지에 대한 자신감을 표명했습니다. 이 회사는 2025년 1월 16일에 제43회 J.P. 모건 헬스케어 컨퍼런스에서 사업 업데이트를 발표할 예정입니다.
Butterfly Network (NYSE: BFLY) a annoncé une croissance préliminaire et non vérifiée du chiffre d'affaires du quatrième trimestre 2024 d'environ 35 % d'une année sur l'autre. L'entreprise de santé numérique, connue pour sa technologie d'échographie portable à base de semi-conducteurs, a déclaré avoir dépassé les attentes avec une croissance accélérée tout au long de 2024.
L'entreprise prévoit de publier les résultats vérifiés du quatrième trimestre et de l'année entière 2024 à la fin du mois de février 2025, ainsi que des prévisions pour 2025. La direction a exprimé sa confiance dans le maintien d'une forte croissance du chiffre d'affaires avec une discipline financière continue à l'avenir. L'entreprise présentera une mise à jour commerciale lors de la 43e Conférence sur les soins de santé J.P. Morgan le 16 janvier 2025.
Butterfly Network (NYSE: BFLY) hat ein vorläufiges, nicht geprüftes Umsatzwachstum von etwa 35 % im Vergleich zum Vorjahr für das vierte Quartal 2024 bekannt gegeben. Das digitale Gesundheitsunternehmen, das für seine tragbare, halbleiterbasierte Ultraschalltechnologie bekannt ist, berichtete, die Erwartungen mit beschleunigtem Wachstum im gesamten Jahr 2024 übertroffen zu haben.
Das Unternehmen plant, die geprüften Ergebnisse des vierten Quartals und des gesamten Jahres 2024 Ende Februar 2025 zu veröffentlichen, zusammen mit einer Prognose für 2025. Das Management äußerte Vertrauen, das starke Umsatzwachstum bei fortgesetzter finanzieller Disziplin aufrechtzuerhalten. Das Unternehmen wird am 43. J.P. Morgan Healthcare Conference am 16. Januar 2025 ein Geschäftsupdate präsentieren.
- 35% year-over-year revenue growth in Q4 2024
- Accelerating growth rate throughout 2024
- Exceeded performance expectations
- Financial results are preliminary and unaudited
- Detailed financial metrics not yet available
Insights
The preliminary Q4 2024 results from Butterfly Network showcase remarkable 35% year-over-year revenue growth, indicating strong market traction for their portable ultrasound technology. A few key points stand out in this preliminary report:
The accelerating growth trajectory throughout 2024 suggests successful market penetration and increasing adoption of their semiconductor-based ultrasound devices. The company's strategic execution appears to be paying off, particularly in terms of sales momentum. However, investors should note that these are unaudited figures and the final audited results could differ.
Looking at the broader market context, Butterfly's performance is particularly noteworthy given the current healthcare technology landscape. The portable ultrasound market is experiencing rapid expansion and Butterfly's growth rate indicates they're capturing a significant share of this opportunity. The company's focus on fiscal discipline alongside growth is a positive signal for potential margin improvements.
From a medical technology perspective, Butterfly's strong growth reflects the increasing adoption of point-of-care ultrasound (POCUS) technology in clinical settings. Their semiconductor-based approach represents a significant technological advantage, making ultrasound more accessible and cost-effective compared to traditional cart-based systems.
The accelerating growth rate suggests that healthcare providers are increasingly recognizing the value proposition of Butterfly's portable ultrasound devices. This technology democratizes access to medical imaging, particularly beneficial for primary care, emergency medicine and remote healthcare settings. The company's intuitive software integration appears to be resonating with healthcare practitioners, addressing the traditional barriers to ultrasound adoption.
The Company will present a business update at the 43rd J.P. Morgan Healthcare Conference on January 16, 2025 at 7:30 am PST.
Joseph DeVivo, Butterfly's President, Chief Executive Officer and Chairman commented, “The Butterfly team closed out 2024 strong, with yet another standout performance in the final quarter. Our preliminary unaudited results show we exceeded expectations again, with our growth rate accelerating throughout the year. This kind of performance doesn’t happen by chance; it’s the result of relentless execution, exceptional products, and a team that’s nothing short of extraordinary. This is Butterfly.”
Heather Getz, Butterfly's Chief Financial and Operations Officer continued, “We expect to report audited fourth quarter and full year 2024 results in late February and to provide 2025 guidance at that time. We’re thrilled to be heading into 2025 with great momentum and expect another year of strong top line growth with continued fiscal discipline.”
Butterfly will participate at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025. Mr. DeVivo will present on Thursday, January 16, 2025, at 7:30 AM PST. A webcast of the presentation will be posted on the Events & Presentations section of the Butterfly investor website, and available for replay until February 15, 2025.
Butterfly has not yet completed its fiscal year-end financial close process for the quarter ended December 31, 2024. This estimate of Butterfly’s year over year revenue growth for the quarter ended December 31, 2024 is preliminary, based on currently available information, has not been audited and is subject to change upon completion of Butterfly’s financial statement closing procedures. Additional information and disclosure would be required for a more complete understanding of Butterfly’s financial position and results of operations as of December 31, 2024. The preliminary financial data included in this release has been prepared by, and is the responsibility of, Butterfly’s management. Deloitte & Touche LLP has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, Deloitte & Touche LLP does not express an opinion or any other form of assurance with respect thereto. The information presented herein should not be considered a substitute for the financial information the Company will file with the
Forward Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believe,” “predict,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, our statements regarding the Company’s estimated fourth quarter revenue growth and its expectations with respect to 2025 financial results. Forward-looking statements are based on our current beliefs and assumptions and on information currently available to us. These forward-looking statements involve significant known and unknown risks and uncertainties and other factors that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside our control and are difficult to predict. Factors that may cause such differences include, but are not limited to: our ability to grow and manage growth effectively; the success, cost, and timing of our product and service development activities; the potential attributes and benefits of our products and services; the degree to which our products and services are accepted by healthcare practitioners and patients for their approved uses; our ability to obtain and maintain regulatory approval for our products, and any related restrictions and limitations of any approved product; our ability to identify, in-license, or acquire additional technology; our ability to maintain our existing license, manufacturing, supply, and distribution agreements; our ability to compete with other companies currently marketing or engaged in the development of products and services that we are currently marketing or developing; changes in applicable laws or regulations; the size and growth potential of the markets for our products and services, and our ability to serve those markets, either alone or in partnership with others; the pricing of our products and services, and reimbursement for medical procedures conducted using our products and services; our estimates regarding expenses, revenue, capital requirements, and needs for additional financing; our financial performance; our ability to raise financing in the future; and other risks and uncertainties indicated from time to time in our most recent Annual Report on Form 10-K, as amended, or in subsequent filings that we make with the Securities and Exchange Commission. We caution that the foregoing list of factors is not exclusive. We caution you not to place undue reliance upon any forward-looking statements, which speak only as of the date of this press release. We do not undertake or accept any obligation or undertake to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based.
About Butterfly Network
Founded by Dr. Jonathan Rothberg in 2011, Butterfly Network is a digital health company with a mission to democratize medical imaging by making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Butterfly created the world's first handheld single-probe, whole-body ultrasound system using semiconductor technology, Butterfly iQ. The company has continued to innovate, leveraging the benefits of Moore’s Law, to launch its second generation Butterfly iQ+ in 2020, and third generation iQ3 in 2024 – each with increased processing power and performance enhancements. The disruptive technology has been recognized by TIME’s Best Inventions, Fast Company’s World Changing Ideas, CNBC Disruptor 50, and MedTech Breakthrough Awards, among other accolades. With its proprietary Ultrasound-on-Chip™ technology, intelligent software, and educational offerings, Butterfly is paving the way to mass adoption of ultrasound for earlier detection and remote management of health conditions around the world. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of
View source version on businesswire.com: https://www.businesswire.com/news/home/20250108005719/en/
Butterfly Investors:
Heather Getz
Chief Financial and Operations Officers, Butterfly Network
investors@butterflynetwork.com
and
Steve Halper
LifeSci Advisors (IR Representative)
646-876-6455
shalper@lifesciadvisors.com
Source: Butterfly Network, Inc.
FAQ
What was Butterfly Network's (BFLY) revenue growth in Q4 2024?
When will Butterfly Network (BFLY) release its full Q4 2024 earnings report?
When will Butterfly Network (BFLY) provide guidance for 2025?
When is Butterfly Network's (BFLY) presentation at the J.P. Morgan Healthcare Conference?
